With growing revenue, Zylox-Tonbridge's operational efficiency continues to rise. In 2024, the Company reduced its R&D, sales, and administrative expense ratios by 20, 9, and 10 percentage points, ...

Wit Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partnership with ...

Zylox-Tonbridge will uphold its commitment to "Innovation for Quality Life," increasing investments in medical technology to provide global patients with high-quality, affordable medical devices ...

Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for ...